Lumiera Health (TSXV:NHP.H) Research & Development: C$0.00 Mil (TTM As of Aug. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lumiera Health Research & Development?

Lumiera Health TSXV:NHP.H Research & Development is C$0.00 Mil as of Aug. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Lumiera Health's Research & Development for the three months ended in Aug. 2023 was C$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Aug. 2023 was C$0.00 Mil.

Lumiera Health  (TSXV:NHP.H) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lumiera Health Research & Development Related Terms

Lumiera Health Research & Development Historical Data

* Premium members only.

The historical data trend for Lumiera Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumiera Health Research & Development Chart

Lumiera Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Nov18 Nov19 Nov20 Nov21 Nov22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.00 0.00 0.00 0.00

Lumiera Health Quarterly Data
Sep18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

Lumiera Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$0.00 Mil mean?
Lumiera Health (TSXV:NHP.H) has a Research & Development of C$0.00 Mil as of Aug. 2023. Research and development expense is the total cost for research and development activities. View historical data on Lumiera Health and its competitors.
Is Lumiera Health's Research & Development too high?
Lumiera Health's current Research & Development is C$0.00 Mil.
How does Lumiera Health's Research & Development compare to ZTS and CTLT?
Lumiera Health's Research & Development of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lumiera Health and its competitors. Lumiera Health's current Research & Development is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumiera Health stock overvalued right now?
Lumiera Health (TSXV:NHP.H) has a current Research & Development of C$0.00 Mil. The current Research & Development is C$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lumiera Health (TSXV:NHP.H), the current Research & Development is C$0.00 Mil as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumiera Health Business Description

Address 4500 Kimber, Suite 26, Saint-Hubert, QC, CAN, J3Y 8K5
Lumiera Health Inc operates as a product development, marketing and sales business of natural products that outsources the manufacturing of products to third-party manufacturing partners/suppliers. The company sells natural and homeopathic products as well as the development and commercialization of botanical-based products for low-risk agricultural use and human health care.